NAD+ Research Guide — Cellular Energy, Sirtuins, and Longevity Science

## Introduction

NAD+ (Nicotinamide Adenine Dinucleotide) is a fundamental coenzyme present in every living cell, from single-celled bacteria to complex multicellular organisms. First discovered in 1906 by British biochemists Arthur Harden and William John Young during their studies of alcoholic fermentation, NAD+ was subsequently characterized as a crucial electron carrier in redox reactions.

NAD+ exists in two interrelated forms: the oxidized form (NAD+) and the reduced form (NADH). The balance between these two states is central to cellular energy metabolism and redox homeostasis. NAD+ is not technically a peptide—it is a dinucleotide composed of two nucleotides joined through their phosphate groups. However, it is routinely studied and administered alongside peptides in research protocols examining longevity, metabolic health, and cellular function.

## Mechanism of Action

NAD+ participates in over 500 enzymatic reactions in mammalian cells. In cellular energy metabolism, NAD+ functions as a critical electron carrier in redox reactions. During glycolysis, each molecule of glucose generates two molecules of NADH from NAD+ through glyceraldehyde-3-phosphate dehydrogenase activity.

Beyond its metabolic electron-shuttling role, NAD+ serves as an essential substrate for three major classes of NAD+-consuming enzymes:

**Sirtuins (SIRT1-7):** This family of NAD+-dependent protein deacetylases links cellular energy status to gene expression regulation. SIRT1 deacetylates histones and transcription factors including PGC-1α, FOXO, p53, and NF-κB. Sirtuin activity is directly proportional to NAD+ availability.

**PARP Enzymes:** PARP1 and PARP2 are activated by DNA single-strand breaks and consume NAD+ to synthesize poly ADP-ribose chains on target proteins, facilitating DNA repair complex recruitment.

**CD38 and CD157:** These ectoenzymes consume NAD+ to generate cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP), both calcium-mobilizing second messengers.

## Research Applications

NAD+ levels decline by approximately 50% between the ages of 40 and 60 in human tissues. Research applications include aging and longevity studies, metabolic research, neurodegenerative disease models, and cardiovascular research.

## Supplementation Strategies

**Subcutaneous Injection:** 100-200 mg, 2-3x per week.

**IV Infusion:** 250-500 mg per session (clinical setting).

**Oral Precursors:** NMN 250-500 mg/day or NR 300-600 mg/day.

## References

- PeptideWiki: NAD+ compound profile

- PubMed: NAD+ metabolism and aging literature